Latrepirdine
Trials 28
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials · 1 missed | ||||||
| Phase 1 | NCT00988624 | Oct → Dec 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00975481 | Oct 2009 → Feb 2010 | Alzheimer disease, Huntington disease | Pfizer | Completed | Missed primary |
| Phase 1 | NCT00990613 | Oct 2009 → Jan 2010 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00931073 | Jul → Oct 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00907322 | Jun → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00831506 | Feb → May 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00825084 | Feb → May 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00831532 | Feb → Aug 2009 | liver failure | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00827034 | Feb → Apr 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00824590 | Feb → Oct 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00829816 | Dec 2008 → Apr 2009 | Alzheimer disease | Medivation, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00788047 | Nov 2008 → Jan 2009 | Alzheimer disease, Huntington disease | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00387270 | Oct 2006 → Mar 2007 | Huntington disease | Medivation, Inc. | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary | ||||||
| Phase 2 | NCT06292351 | Dec 2023 → Jan 2025 | Alzheimer disease | Bigespas LTD | Completed | Met primary |
| Phase 2 | NCT01066481 | Apr 2010 → Mar 2012 | Alzheimer disease | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00704782 | Apr 2008 → Aug 2010 | Alzheimer disease | Medivation, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00497159 | Jul 2007 → Jun 2008 | Huntington disease | Medivation, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00377715 | Sep 2005 → Aug 2006 | Alzheimer disease | Medivation, Inc. | Completed | Met primary |
| Phase 310 trials · 1 missed | ||||||
| Phase 3 | NCT01152216 | Apr 2010 → May 2012 | Alzheimer disease | Medivation, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01066546 | Apr → Jul 2010 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01085266 | Feb 2010 → Jun 2011 | Huntington disease | Medivation, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00954590 | Oct 2009 → Aug 2010 | — | Medivation, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00912288 | Sep 2009 → Aug 2010 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00939783 | Sep 2009 → Aug 2010 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00920946 | Jul 2009 → Jul 2011 | Huntington disease | Medivation, Inc. | Completed | Missed primary |
| Phase 3 | NCT00829374 | Mar 2009 → Dec 2011 | Alzheimer disease | Medivation, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00838110 | Feb 2009 → Jan 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00675623 | May 2008 → Dec 2009 | Alzheimer disease | Medivation, Inc. | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latrepirdine | “Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial...” PMID 23108692 ↗ Jan 20137“A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release...” NCT00990613 ↗ “An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease” NCT01066546 ↗ “A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)” NCT00988624 ↗ “A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users” NCT00975481 ↗ “evaluate efficacy and safety of Latrepirdine polymorph DMB-I in 26-week” PMID 42141012 ↗ May 2026 “Dimebon (latrepirdine)” NCT00954590 ↗ “Dimebon (latrepirdine)” NCT01085266 ↗ |
| Known as | Dimebolin | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | Dimebolin dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | Dimebolin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | Dimebon | “B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant...” NCT00827034 ↗ |
| Known as | Dimebon dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | DMB-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06292351 ↗ |
| Known as | Latrepirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | LATREPIRDINE DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL589390 ↗ |
| Known as | PF 01913539 | “A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon...” NCT00931073 ↗10“A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6...” NCT00788047 ↗ “A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With...” NCT00838110 ↗ “A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics...” NCT00827034 ↗ “A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired...” NCT00824590 ↗ “An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease” NCT01066546 ↗ “An Open Label Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon (PF 01913539) In Patients With Alzheimer's Disease” NCT00939783 ↗ “A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects” NCT00825084 ↗ “Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects” NCT00831506 ↗ “Dimebon [Pf-01913539]” NCT00831532 ↗ |
| Modality | Small molecule | “Latrepirdine is an orally administered experimental small molecule” PMID 23108692 ↗ Jan 2013 |
| Route | Oral | “receive oral dimebon, 20 mg three times a day” PMID 18640457 ↗ Jul 2008 |